_____________________________
_____________________________
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest
event reported):
March 7, 1997
XYTRONYX, INC.
---------------------------
(Exact name of registrant as specified in its charter)
Delaware
----------------
(State or other jurisdiction of incorporation)
0-14838 36-3258753
----------------- ------------------------------
(Commission File Number) (IRS Employer Identification Number)
6730 Mesa Ridge Rd.
Suite A
San Diego, California 92121
--------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (619) 550-3900
--------------
Item 5. Other Events.
News release dated March 7, 1997, (the "News Release") announcing that the
Company completed its previously announced sale of $10 million of Premium
Preferred Units-TM- including $3.345 million raised on December 19, 1996,
resulting in aggregate net proceeds of $8.7 million. The Company also announced
that a successful animal study suggests IN VIVO proof of principle for its
Photodynamic Immunotherapy-TM- (PDIT-TM-) for the treatment of metastatic breast
cancer. In addition, together with Binary Therapeutics, Inc. (BTI), Xytronyx
has agreed to extend the option period during which Xytronyx may elect to
consummate the merger with BTI, the holder of certain photodynamic therapy
technology. The News Release filed as Exhibit 99.1 hereto, is hereby
incorporated into this Report by reference.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
(c) EXHIBITS. The following exhibit accompanies this Report:
Exhibit
Number Exhibit Description
------ -------------------
99.1
News release dated March 7, 1997 announcing that the Company
completed its previously announced sale of $10 million of
Premium Preferred Units-TM- including $3.345 million raised
on December 19, 1996, resulting in aggregate net proceeds of
$8.7 million. The Company also announced that a successful
animal study suggests IN VIVO proof of principle for its
Photodynamic Immunotherapy-TM- (PDIT-TM-) for the treatment
of metastatic breast cancer. In addition, together with
Binary Therapeutics, Inc. (BTI), Xytronyx has agreed to
extend the option period during which Xytronyx may elect to
consummate the merger with BTI, the holder of certain
photodynamic therapy technology.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
XYTRONYX, INC.
By: /s/ H. Laurence Shaw
--------------------------
H. Laurence Shaw
Date: March 10, 1997 Chairman and Chief Executive Officer
2
INDEX TO EXHIBITS
Exhibit Sequentially
Number Description of Exhibit Numbered Page
- ------ ---------------------- -------------
99.1 News release dated March 7, 1997 announcing
that that the Company completed its previously
announced sale of $10 million of Premium
Preferred Units-TM- including $3.345 million
raised on December 19, 1996, resulting in
aggregate net proceeds of $8.7 million. The
Company also announced that a successful animal
study suggests IN VIVO proof of principle for
its Photodynamic Immunotherapy-TM- (PDIT-TM-)
for the treatment of metastatic breast cancer.
In addition, together with Binary Therapeutics,
Inc. (BTI), Xytronyx has agreed to extend the
option period during which Xytronyx may elect
to consummate the merger with BTI, the holder
of certain photodynamic therapy technology.
3